High Cost Impacts PCSK9 Inhibitor Access

Mark Tesell, PharmD, BCPS, discusses how the high cost of PCSK9 inhibitors effected uptake of the cholesterol-lowering drug.

Mark Tesell, PharmD, BCPS, discusses how the high cost of PCSK9 inhibitors effected uptake of the cholesterol-lowering drug.

Related Videos
Related Content

FDA Grants Orphan Drug Designation to Belimumab for Systemic Sclerosis Treatment

February 6th 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

Biosimilars Found to Produce Cost Savings Despite Increased Consumption Volume

February 3rd 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

Medicaid Patients With NSCLC May Be Undertreated With Life-prolonging Targeted Therapies

February 1st 2023

First Humira Biosimilar Launches in the United States

February 1st 2023

FDA Grants Orphan Drug Designation to Belimumab for Systemic Sclerosis Treatment

February 6th 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

Biosimilars Found to Produce Cost Savings Despite Increased Consumption Volume

February 3rd 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

Medicaid Patients With NSCLC May Be Undertreated With Life-prolonging Targeted Therapies

February 1st 2023

First Humira Biosimilar Launches in the United States

February 1st 2023

FDA Grants Orphan Drug Designation to Belimumab for Systemic Sclerosis Treatment

February 6th 2023

Pharmacy Focus: Psychedelic Pharmacy - Understanding Natural vs. Synthetic Psychedelics

January 13th 2023

Biosimilars Found to Produce Cost Savings Despite Increased Consumption Volume

February 3rd 2023

Pharmacy Focus: Public Health Matters- Celebrating American Pharmacist Month Part 2 with Autumn Zuckerman

October 13th 2022

Medicaid Patients With NSCLC May Be Undertreated With Life-prolonging Targeted Therapies

February 1st 2023

First Humira Biosimilar Launches in the United States

February 1st 2023
About Us
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.